a cure for hep c, aids, the flu and dengue..., page-118

Interesting to note that BIT is the 45th most tipped stock out of a pool of 520. Proof of concept won't occur during this month but the safety data is accumulating every day. Some patients have now safely completed a combination (BIT225/interferon/ribavirin) trial of a drug that has had proven activity as a monotherapy in patients (demonstrated Phase Ib) and is known to be highly synergistic as a combination treatment. This initial safety data is of major significance. The risk of this trial diminishes daily so I can't see the share price remaining this low for much longer. Happy tipping.